<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on July 28, 2020</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT04244149</url>
  </required_header>
  <id_info>
    <org_study_id>UEM0003</org_study_id>
    <nct_id>NCT04244149</nct_id>
  </id_info>
  <brief_title>Effect of an Exercise Bout in Plasma and Fecal Profile</brief_title>
  <acronym>MEMEX</acronym>
  <official_title>Exploring the Effect of Exhaustive Exercise From a Metabolomic and Metagenomic Approach</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Universidad Europea de Madrid</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Universidad Europea de Madrid</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
    <is_fda_regulated_drug>No</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
  </oversight_info>
  <brief_summary>
    <textblock>
      The aim of this project is to study the effect of a bout of exercise on the metabolomic
      profile of plasma and feces as well as its influence on the intestinal microbiota.
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      The practice of physical exercise has numerous health benefits, preventing the appearance and
      development of cardiovascular diseases and various types of cancer. Exercise causes changes
      in the vascular, muscular and pulmonary systems, etc. One of the benefits that can result
      from exercise modification of the intestinal microbiota and its metabolic profile. In order
      to identify the potential changes that exercise has on the intestinal microbiota and its
      metabolic profile, the purpose of this study is to identify changes in the plasma and fecal
      metabolome and in fecal microbiota associated with a bout of exercise
    </textblock>
  </detailed_description>
  <overall_status>Completed</overall_status>
  <start_date type="Actual">February 20, 2020</start_date>
  <completion_date type="Actual">March 13, 2020</completion_date>
  <primary_completion_date type="Actual">March 10, 2020</primary_completion_date>
  <phase>N/A</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>N/A</allocation>
    <intervention_model>Single Group Assignment</intervention_model>
    <primary_purpose>Basic Science</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Plasma metabolome profile</measure>
    <time_frame>Changes from baseline to 30 min after the exercise intervention</time_frame>
    <description>Abundance of blood metabolites, metabolic networks, and metabolic pathways activity</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Fecal microbiota</measure>
    <time_frame>Changes from baseline to 30 min after the exercise intervention</time_frame>
    <description>Abundance of gut microbial taxa, communities, and metabolic pathways activity</description>
  </primary_outcome>
  <number_of_arms>1</number_of_arms>
  <enrollment type="Actual">40</enrollment>
  <condition>Healthy</condition>
  <arm_group>
    <arm_group_label>Intervention group</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Participants will exert an exercise prolonged session</description>
  </arm_group>
  <intervention>
    <intervention_type>Other</intervention_type>
    <intervention_name>Prolonged Exercise session</intervention_name>
    <description>After a standardized warm-up of 10 minutes of continuous running on a treadmill at 60% of their maximum heart rate (HRmax), subjects will perform a maximum oxygen consumption test (VO2max) with a gas analyzer (UltimaTM Series, MGC Diagnostic Corporation, St. Paul, MN, USA. The protocol will start with a slope of 1% at a speed of 10 km/h, with increments of 0.3 km/h every 30 s until volitional exhaustion. Finally, ten minutes after the treadmill test, volunteers will run 1 kilometer (t1km) as fast as possible and the time needed to cover the distance will be recorded.</description>
    <arm_group_label>Intervention group</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  18-45 years of age

          -  high physical condition (VO2 ≥ 55 ml/kg/min)

          -  BMI 18-25 kg/m2

        Exclusion Criteria:

          -  antibiotics intake during 3 months prior to the study,

          -  smoking

          -  nutritional complements

          -  ergogenic complements

          -  prebiotics

          -  probiotics

          -  vegetarian or vegan diet

          -  chronic medication

          -  gastrointestinal surgery

          -  Any diagnosed disease
      </textblock>
    </criteria>
    <gender>Male</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>45 Years</maximum_age>
    <healthy_volunteers>Accepts Healthy Volunteers</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Mar Larrosa, PhD</last_name>
    <role>Principal Investigator</role>
    <affiliation>Universidad Europea de Madrid</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>Maria del Mar Larrosa Pérez</name>
      <address>
        <city>Villaviciosa de Odon</city>
        <state>Madrid</state>
        <zip>28670</zip>
        <country>Spain</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>Spain</country>
  </location_countries>
  <verification_date>June 2020</verification_date>
  <study_first_submitted>January 20, 2020</study_first_submitted>
  <study_first_submitted_qc>January 24, 2020</study_first_submitted_qc>
  <study_first_posted type="Actual">January 28, 2020</study_first_posted>
  <last_update_submitted>June 18, 2020</last_update_submitted>
  <last_update_submitted_qc>June 18, 2020</last_update_submitted_qc>
  <last_update_posted type="Actual">June 22, 2020</last_update_posted>
  <responsible_party>
    <responsible_party_type>Principal Investigator</responsible_party_type>
    <investigator_affiliation>Universidad Europea de Madrid</investigator_affiliation>
    <investigator_full_name>Mar Larrosa</investigator_full_name>
    <investigator_title>Tenure Professor</investigator_title>
  </responsible_party>
  <patient_data>
    <sharing_ipd>Yes</sharing_ipd>
    <ipd_description>All IPD that underlie results in a publication. Metagenomic raw data will be deposited in the http://www.ncbi.nlm.nih.gov/sra</ipd_description>
    <ipd_info_type>Study Protocol</ipd_info_type>
    <ipd_info_type>Statistical Analysis Plan (SAP)</ipd_info_type>
    <ipd_info_type>Informed Consent Form (ICF)</ipd_info_type>
    <ipd_time_frame>Upon publication</ipd_time_frame>
    <ipd_access_criteria>Data will be in a public repository</ipd_access_criteria>
  </patient_data>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

